Pseudomonas is not one thing in bronchiectasis

Design

Cross-sectional metagenomic analysis with small longitudinal sub-analyses and transition probability estimation

Population

Sputum metagenomes from 600 individuals with bronchiectasis across ten countries; longitudinal subsets of six (exacerbation) and eleven (eradication)

Primary outcome

Derivation of Pseudomonas abundance and interaction subgroups and their relation to severity and exacerbation risk

Effect

Four abundotypes correlating with severity, symptoms and lung function but comparable exacerbation risk; four interactotypes stratifying exacerbation risk, with the Streptococcus-interacting group lowest and the Neisseria-interacting and mixed groups at 1.45-fold (p=0.037) and 1.44-fold (p=0.048) higher exacerbation rates

Pseudomonas aeruginosa in bronchiectasis is treated as a binary — present or absent — and its presence drives eradication attempts, long-term antibiotics and prognosis. Yet outcomes among colonised patients vary enormously. This study analysed sputum metagenomes from 600 people with bronchiectasis across ten countries to ask whether the variation lies in the microbial ecology.

Two independent classifications emerged. Four abundotypes, based on how much Pseudomonas there is relative to everything else — Pseudomonas-dominant, moderately dominant, other-microbe-dominant, and high diversity — correlated with bronchiectasis severity, symptoms and lung function but carried comparable exacerbation risk. Four interactotypes, based on which organisms Pseudomonas interacts with, did the opposite: they did not track severity but did stratify exacerbation risk. The Streptococcus-interacting group had the lowest risk, while the Neisseria-interacting and mixed groups carried about 1.45-fold and 1.44-fold higher exacerbation rates.

Small longitudinal subsets hint at why the two differ. Through exacerbations, abundotypes stayed stable while interactotypes shifted substantially; during eradication, abundotypes moved in a structured way while interactotypes did not. Those observations rest on six and eleven patients respectively, and the authors label them hypothesis-generating.

The conceptual gain is real: how much Pseudomonas there is tells you how damaged the lung is, and who it is interacting with may tell you what is about to happen.

• Nothing to order — metagenomic profiling is not a clinical test in bronchiectasis
• Continue standard culture-based management and eradication protocols
• Note the separation: abundance tracks severity, interaction tracks exacerbation risk
• The longitudinal observations rest on six and eleven patients and are explicitly exploratory
• Expect microbial interaction, not just abundance, in future stratification of this disease

Why it matters

It offers an explanation for why Pseudomonas colonisation predicts such different courses in different patients.

Don't overread it

The longitudinal findings come from six patients through exacerbation and eleven through eradication; these are hypothesis-generating observations, not results.

The statistics, in plain English

Exacerbation rate ratios of 1.45 and 1.44 with p values of 0.037 and 0.048 sit just inside conventional significance across four compared groups with no stated correction for multiple comparisons, so they should be treated as provisional. The third group's 1.32-fold increase was not significant, which is consistent with all three being versions of the same modest effect. The longitudinal transition analyses, on six and eleven patients, cannot support any quantitative claim and the authors do not make one.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.